NASDAQ:XRAY - DENTSPLY SIRONA Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$36.31 -0.16 (-0.44 %)
(As of 12/9/2018 04:00 PM ET)
Previous Close$36.31
Today's Range$35.97 - $36.99
52-Week Range$33.93 - $68.47
Volume1.95 million shs
Average Volume2.85 million shs
Market Capitalization$8.08 billion
P/E Ratio13.65
Dividend Yield0.96%
DENTSPLY SIRONA Inc. designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers. The company also offers dental laboratory products, such as dental prosthetics that include artificial teeth, precious metal dental alloys, dental ceramics, and crown and bridge materials. In addition, it provides dental technology products, including dental implants and related scanning equipment, treatment software, and orthodontic appliances for dental practitioners and specialist, and dental laboratories; and dental equipment, such as treatment centers, imaging equipment, and computer aided design and machining systems for dental practitioners and laboratories. Further, the company offers healthcare consumable products, such as urology catheters, various surgical products, medical drills, and other non-medical products. It markets and sells dental products through distributors, dealers, and importers to dentists, dental hygienists, dental assistants, dental laboratories, and dental schools; and urology products directly to patients, as well as through distributors to urologists, urology nurses, and general practitioners. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1899 and is headquartered in York, Pennsylvania.

Receive XRAY News and Ratings via Email

Sign-up to receive the latest news and ratings for XRAY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Dental equipment & supplies
Sub-IndustryHealth Care Supplies
Current SymbolNASDAQ:XRAY
Previous Symbol


Debt-to-Equity Ratio0.31
Current Ratio1.76
Quick Ratio1.14


Trailing P/E Ratio13.65
Forward P/E Ratio18.43
P/E Growth2.21

Sales & Book Value

Annual Sales$3.99 billion
Price / Sales2.02
Cash Flow$11.2415 per share
Price / Cash Flow3.23
Book Value$28.86 per share
Price / Book1.26


EPS (Most Recent Fiscal Year)$2.66
Net Income$-1,550,000,000.00
Net Margins-41.97%
Return on Equity8.68%
Return on Assets5.35%


Outstanding Shares222,550,000
Market Cap$8.08 billion

DENTSPLY SIRONA (NASDAQ:XRAY) Frequently Asked Questions

What is DENTSPLY SIRONA's stock symbol?

DENTSPLY SIRONA trades on the NASDAQ under the ticker symbol "XRAY."

How often does DENTSPLY SIRONA pay dividends? What is the dividend yield for DENTSPLY SIRONA?

DENTSPLY SIRONA announced a quarterly dividend on Tuesday, June 26th. Investors of record on Friday, September 28th will be given a dividend of $0.0875 per share on Friday, October 12th. This represents a $0.35 annualized dividend and a dividend yield of 0.96%. The ex-dividend date is Thursday, September 27th. View DENTSPLY SIRONA's Dividend History.

How were DENTSPLY SIRONA's earnings last quarter?

DENTSPLY SIRONA Inc (NASDAQ:XRAY) issued its quarterly earnings data on Thursday, November, 8th. The medical instruments supplier reported $0.38 earnings per share for the quarter, missing analysts' consensus estimates of $0.46 by $0.08. The medical instruments supplier earned $928.40 million during the quarter, compared to the consensus estimate of $951.58 million. DENTSPLY SIRONA had a negative net margin of 41.97% and a positive return on equity of 8.68%. The company's revenue for the quarter was down 8.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.70 EPS. View DENTSPLY SIRONA's Earnings History.

When is DENTSPLY SIRONA's next earnings date?

DENTSPLY SIRONA is scheduled to release their next quarterly earnings announcement on Thursday, March 7th 2019. View Earnings Estimates for DENTSPLY SIRONA.

What guidance has DENTSPLY SIRONA issued on next quarter's earnings?

DENTSPLY SIRONA issued an update on its FY18 earnings guidance on Thursday, November, 8th. The company provided earnings per share guidance of $2.00-2.15 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.07. DENTSPLY SIRONA also updated its FY 2018 guidance to $2.00 EPS.

What price target have analysts set for XRAY?

14 brokers have issued 1-year target prices for DENTSPLY SIRONA's shares. Their forecasts range from $38.00 to $75.00. On average, they expect DENTSPLY SIRONA's stock price to reach $51.50 in the next twelve months. This suggests a possible upside of 41.8% from the stock's current price. View Analyst Price Targets for DENTSPLY SIRONA.

What is the consensus analysts' recommendation for DENTSPLY SIRONA?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DENTSPLY SIRONA in the last year. There are currently 8 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for DENTSPLY SIRONA.

What are Wall Street analysts saying about DENTSPLY SIRONA stock?

Here are some recent quotes from research analysts about DENTSPLY SIRONA stock:
  • 1. According to Zacks Investment Research, "DENTSPLY saw year-over-year improvement in revenues in recent times. Also, rising sales in Europe and rest of the world buoy optimism. The company’s agreement with MedTech bigwig Patterson Companies in Canada is likely to drive sales. The recent launch of Azento single tooth replacement solution is also a positive development. However, the company incurred a huge goodwill and intangible impairment charge recently. Impairment charges in the Technologies and Equipment and Consumable units are a concern. Moreover, the company saw lower-than-anticipated revenues and margin at the Imaging, CAD and CAM businesses. Orthodontic product platforms put up a weak show of late. A lowered guidance for 2018 is discouraging. Dented margins and surging operating losses are likely to impede growth. The company also has a high level of long-term debt which adds to the woes. DENTSPLY underperformed its industry in a year’s time." (11/17/2018)
  • 2. Barrington Research analysts commented, "We suspect modest progress can be made in 2019, but this plan will take two to three years, at least, to impact in a material way – even in management’s view." (11/9/2018)
  • 3. HC Wainwright analysts commented, "Our price target is derived from a comparable universe-based approach, which utilizes a price-to-earnings (P/E) multiple calculated from a group of peer companies in the medical and dental equipment arenas." (8/31/2018)
  • 4. Jefferies Financial Group Inc analysts commented, "Dynavax provided Phase 1b/2 updates on TLR9 agonist, SD-101 in combination with Keytruda, for head and neck squamous cell carcinoma (HNSCC) and metastatic melanoma at AACR." (4/16/2018)

Has DENTSPLY SIRONA been receiving favorable news coverage?

News articles about XRAY stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. DENTSPLY SIRONA earned a daily sentiment score of 0.8 on InfoTrie's scale. They also assigned headlines about the medical instruments supplier a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future.

Who are some of DENTSPLY SIRONA's key competitors?

Some companies that are related to DENTSPLY SIRONA include Straumann (SAUHF), Sartorius (SARTF), Nobel Biocare (NBHGF), Biomerica (BMRA), BIOLASE (BIOL) and Remedent (REMI).

Who are DENTSPLY SIRONA's key executives?

DENTSPLY SIRONA's management team includes the folowing people:
  • Mr. Nicholas William Alexos, Exec. VP & CFO (Age 54)
  • Mr. Keith John Ebling, EVP, Gen. Counsel & Sec. (Age 49)
  • Ms. Maureen J. MacInnis, Sr. VP, Chief HR Officer & Communications (Age 57)
  • Mr. Robert J. Size, Interim Pres & COO (Age 59)
  • Mr. Donald M. Casey Jr., CEO & Director (Age 58)

Who are DENTSPLY SIRONA's major shareholders?

DENTSPLY SIRONA's stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (10.40%), BlackRock Inc. (6.33%), Veritas Asset Management LLP (5.36%), Mackenzie Financial Corp (3.86%), First Eagle Investment Management LLC (2.77%) and Morgan Stanley (2.36%). Company insiders that own DENTSPLY SIRONA stock include Arthur D Kowaloff, Bret W Wise, Christopher T Clark, Donald M Jr Casey, Eric Brandt, Francis J Lunger, James G Mosch, Mark Thierer, Markus Boehringer, Michael C Alfano, Michael J Coleman, Nicholas W Alexos and Ulrich Michel. View Institutional Ownership Trends for DENTSPLY SIRONA.

Which major investors are selling DENTSPLY SIRONA stock?

XRAY stock was sold by a variety of institutional investors in the last quarter, including Brown Brothers Harriman & Co., Macquarie Group Ltd., Bank of New York Mellon Corp, Renaissance Technologies LLC, Thompson Siegel & Walmsley LLC, Massachusetts Financial Services Co. MA, Neuberger Berman Group LLC and Prudential Financial Inc.. Company insiders that have sold DENTSPLY SIRONA company stock in the last year include Eric Brandt, Markus Boehringer, Michael C Alfano and Michael J Coleman. View Insider Buying and Selling for DENTSPLY SIRONA.

Which major investors are buying DENTSPLY SIRONA stock?

XRAY stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, First Eagle Investment Management LLC, Mackenzie Financial Corp, ValueAct Holdings L.P., Veritas Asset Management LLP, Nuance Investments LLC, Schroder Investment Management Group and Manitou Investment Management Ltd.. Company insiders that have bought DENTSPLY SIRONA stock in the last two years include Donald M Jr Casey, Mark Thierer and Nicholas W Alexos. View Insider Buying and Selling for DENTSPLY SIRONA.

How do I buy shares of DENTSPLY SIRONA?

Shares of XRAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is DENTSPLY SIRONA's stock price today?

One share of XRAY stock can currently be purchased for approximately $36.31.

How big of a company is DENTSPLY SIRONA?

DENTSPLY SIRONA has a market capitalization of $8.08 billion and generates $3.99 billion in revenue each year. The medical instruments supplier earns $-1,550,000,000.00 in net income (profit) each year or $2.66 on an earnings per share basis. DENTSPLY SIRONA employs 16,100 workers across the globe.

What is DENTSPLY SIRONA's official website?

The official website for DENTSPLY SIRONA is

How can I contact DENTSPLY SIRONA?

DENTSPLY SIRONA's mailing address is 221 WEST PHILADELPHIA STREET, YORK PA, 17401. The medical instruments supplier can be reached via phone at 717-845-7511 or via email at [email protected]

MarketBeat Community Rating for DENTSPLY SIRONA (NASDAQ XRAY)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  307 (Vote Outperform)
Underperform Votes:  320 (Vote Underperform)
Total Votes:  627
MarketBeat's community ratings are surveys of what our community members think about DENTSPLY SIRONA and other stocks. Vote "Outperform" if you believe XRAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XRAY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/9/2018 by Staff

Featured Article: What are no-load funds?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel